

Figure. S1. TCGA sarcoma patient data of Myc expression was downloaded from OncoLnc (<http://www.oncolnc.org/>). Correlation between the expression of Myc in sarcoma patients and survival (Kaplan-Meier survival curve analysis, $p= 0.09$).

Figure. S2. Confirmation of Myc knockdown by siRNA in immunofluorescence assay. Expression of Myc in KHOS and U2OS cells was assessed by immunofluorescence with antibodies to Myc (green) and β -actin (red). Hoechst 33342 was added to counterstain the cell nucleus (blue). Green fluorescence of Myc protein was mainly localized in the nucleus of osteosarcoma cells.

Figure. S3. Myc inhibitor 10058-F4 inhibits osteosarcoma cell proliferation and decreases viability in a dose and time-dependent manner (** $p < 0.01$, *** $p < 0.001$ as compared with the untreated control group). Osteosarcoma cell viability was measured by MTT after 2, 3 and 5 days incubation with different concentrations of Myc inhibitor.